Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Rexahn Pharmaceuticals

DB:R3X
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
R3X
DB
$7M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • Rexahn Pharmaceuticals has significant price volatility in the past 3 months.
R3X Share Price and Events
7 Day Returns
-5.6%
DB:R3X
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-74.2%
DB:R3X
-13.2%
DE Biotechs
-20.9%
DE Market
R3X Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rexahn Pharmaceuticals (R3X) -5.6% -23.1% -16.4% -74.2% -97.8% -98.1%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • R3X underperformed the Biotechs industry which returned -13.2% over the past year.
  • R3X underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
R3X
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Rexahn Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Rexahn Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €1.53.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rexahn Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rexahn Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:R3X PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.18
NasdaqCM:REXN Share Price ** NasdaqCM (2020-04-03) in USD $1.78
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rexahn Pharmaceuticals.

DB:R3X PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:REXN Share Price ÷ EPS (both in USD)

= 1.78 ÷ -2.18

-0.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rexahn Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Rexahn Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Rexahn Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:R3X PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rexahn Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rexahn Pharmaceuticals's assets?
Raw Data
DB:R3X PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.48
NasdaqCM:REXN Share Price * NasdaqCM (2020-04-03) in USD $1.78
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:R3X PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:REXN Share Price ÷ Book Value per Share (both in USD)

= 1.78 ÷ 2.48

0.72x

* Primary Listing of Rexahn Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rexahn Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Rexahn Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Rexahn Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Rexahn Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rexahn Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rexahn Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Rexahn Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Rexahn Pharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Rexahn Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:R3X Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:R3X Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:R3X Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:R3X Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -10 -9
2019-09-30 -13 -10
2019-06-30 -15 -13
2019-03-31 -18 -15
2018-12-31 -19 -14
2018-09-30 -18 -15
2018-06-30 -17 -11
2018-03-31 -17 -6
2017-12-31 -15 -25
2017-09-30 -13 -22
2017-06-30 -13 -24
2017-03-31 -14 -27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Rexahn Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Rexahn Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:R3X Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Rexahn Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:R3X Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:R3X Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.18
2019-09-30 -2.66
2019-06-30 -3.93
2019-03-31 -4.83
2018-12-31 -5.25
2018-09-30 -5.64
2018-06-30 -4.11
2018-03-31 -2.35
2017-12-31 -11.08
2017-09-30 -10.45
2017-06-30 -12.12
2017-03-31 -14.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rexahn Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Rexahn Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Rexahn Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Rexahn Pharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Rexahn Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rexahn Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Rexahn Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rexahn Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rexahn Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Rexahn Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rexahn Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Rexahn Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rexahn Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:R3X Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -8.64 5.74 5.48
2019-09-30 -9.88 6.42 7.75
2019-06-30 -13.26 7.07 9.51
2019-03-31 -14.64 7.30 11.29
2018-12-31 -14.37 7.43 13.11
2018-09-30 -14.84 6.83 13.64
2018-06-30 -10.54 6.61 13.40
2018-03-31 -5.76 6.78 12.51
2017-12-31 -25.29 6.64 10.72
2017-09-30 -22.23 6.84 9.54
2017-06-30 -24.06 6.68 9.19
2017-03-31 -26.77 6.62 8.88
2016-12-31 -9.31 6.32 10.09
2016-09-30 -11.63 5.94 10.92
2016-06-30 -12.79 6.08 11.73
2016-03-31 -14.26 5.99 12.72
2015-12-31 -14.38 6.12 12.15
2015-09-30 -13.74 6.30 11.45
2015-06-30 -11.62 6.06 10.17
2015-03-31 -8.19 6.28 8.64
2014-12-31 -18.52 6.25 7.02
2014-09-30 -19.03 6.34 5.79
2014-06-30 -19.27 5.96 4.75
2014-03-31 -22.57 5.01 3.97
2013-12-31 -9.50 4.73 3.25
2013-09-30 -6.84 3.64 2.52
2013-06-30 -7.68 3.31 2.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rexahn Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rexahn Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rexahn Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rexahn Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rexahn Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Rexahn Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rexahn Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rexahn Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rexahn Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rexahn Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Rexahn Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rexahn Pharmaceuticals Company Filings, last reported 3 months ago.

DB:R3X Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 9.96 0.00 12.22
2019-09-30 11.76 0.00 13.91
2019-06-30 13.62 0.00 16.26
2019-03-31 15.94 0.00 18.02
2018-12-31 10.56 0.00 14.73
2018-09-30 6.41 0.00 12.57
2018-06-30 11.42 0.00 16.74
2018-03-31 14.97 0.00 21.18
2017-12-31 16.77 0.00 26.83
2017-09-30 15.12 0.00 23.20
2017-06-30 15.90 0.00 26.78
2017-03-31 1.13 0.00 18.50
2016-12-31 17.06 0.00 20.32
2016-09-30 17.24 0.00 21.81
2016-06-30 15.81 0.00 19.40
2016-03-31 17.21 0.00 24.47
2015-12-31 18.78 0.00 23.44
2015-09-30 17.71 0.00 21.46
2015-06-30 21.43 0.00 25.98
2015-03-31 23.38 0.00 29.39
2014-12-31 26.58 0.00 32.70
2014-09-30 28.60 0.00 35.59
2014-06-30 30.31 0.00 38.20
2014-03-31 28.03 0.00 40.17
2013-12-31 12.63 0.00 18.79
2013-09-30 9.85 0.00 14.97
2013-06-30 5.50 0.00 10.08
  • Rexahn Pharmaceuticals has no debt.
  • Rexahn Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rexahn Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • Rexahn Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 6.2% each year.
X
Financial health checks
We assess Rexahn Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rexahn Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Rexahn Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rexahn Pharmaceuticals dividends.
If you bought €2,000 of Rexahn Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rexahn Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rexahn Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:R3X Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:R3X Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rexahn Pharmaceuticals has not reported any payouts.
  • Unable to verify if Rexahn Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rexahn Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rexahn Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Rexahn Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rexahn Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rexahn Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Rexahn Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Doug Swirsky
COMPENSATION $1,184,354
AGE 50
TENURE AS CEO 1.4 years
CEO Bio

Mr. Douglas J. Swirsky, also known as, Doug, CPA, and CFA has been President of Rexahn Pharmaceuticals, Inc. since January 2, 2018 and serves as its Chief Executive Officer and Director since November 14, 2018. Mr. Swirsky served as Corporate Secretary and Chief Financial Officer of Rexahn Pharmaceuticals, Inc. January 2018 to November 2018. He served as the Chief Executive Officer and President of GenVec, Inc. since 2014 until June 16, 2017 and served as its Corporate Secretary since September 18, 2006 until June 16, 2017. He served as the Chief Financial Officer of GenVec, Inc. from September 18, 2006 to December 2014 and served as its Treasurer since September 18, 2006. He served as Principal Accounting Officer at GenVec, Inc. until December 2014and served as its Senior Vice President. He served as the Managing Director and the Head of Life Sciences Investment Banking of Stifel Nicolaus from 2005 to 2006 and Legg Mason from 2002 to 2005. He held investment-banking positions at UBS, PaineWebber and Morgan Stanley. His experience includes positions in public accounting and consulting. He has been Board Chairman of Cellectar Biosciences, Inc. since December 12, 2017. He has been the Chairman of the Board at Fibrocell Science, Inc. since December 19, 2016. He served as an Independent Director of PolyMedix, Inc. since June 30, 2009 until March 2013 and Fibrocell Science, Inc. since March 2013. He has been a Director at Cellectar Biosciences, Inc. since April 2017. He has been a Non-Executive Independent Director at Pernix Therapeutics Holdings, Inc. since November 15, 2017. Mr. Swirsky has been a Member of the Business Advisory Board at Calibrant Biosystems, Inc. since August 2008. He served as a Director of GenVec, Inc. since September 18, 2013 until June 16, 2017. Mr. Swirsky is a Certified Public Accountant and Chartered Financial Analyst. Mr. Swirsky received his B.S. in Business in Administration in Accounting from Boston University in the year 1989 to 1992 and Masters in Business Administration from the Kellogg School of Management at Northwestern University in the year 1996 to 1997.

CEO Compensation
  • Insufficient data for Doug to compare compensation growth.
  • Doug's remuneration is higher than average for companies of similar size in Germany.
Management Team

Doug Swirsky

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
50
TENURE
1.4 yrs

Madhukar Trivedi

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the Rexahn Pharmaceuticals board of directors in years:

5.3
Average Tenure
60
Average Age
  • The tenure for the Rexahn Pharmaceuticals board of directors is about average.
Board of Directors

Peter Brandt

TITLE
Chairman
COMPENSATION
$106K
AGE
62
TENURE
4.8 yrs

Doug Swirsky

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
50
TENURE
1.4 yrs

Charles Beever

TITLE
Independent Director
COMPENSATION
$91K
AGE
66
TENURE
13.9 yrs

Michael Thase

TITLE
Chairman of the Depression Scientific Advisory Board
TENURE
9.8 yrs

Rick Rodgers

TITLE
Independent Director
COMPENSATION
$91K
AGE
52
TENURE
5.3 yrs

Kwang Cheong

TITLE
Independent Director
COMPENSATION
$82K
AGE
58
TENURE
13.9 yrs

Maurizio Fava

TITLE
Member of Scientific Advisory Board
TENURE
9.8 yrs

Ben Price

TITLE
Independent Director
COMPENSATION
$86K
AGE
63
TENURE
1.4 yrs

Lara Sullivan

TITLE
Independent Director
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Rexahn Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rexahn Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer; and RX-5902 that is in Phase IIa clinical trials to treat patients with metastatic triple negative breast cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma, as well as RX-0047 that is in preclinical development stage. The company has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; Merck Sharp & Dohme B.V.; and BioSense Global LLC. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.

Details
Name: Rexahn Pharmaceuticals, Inc.
R3X
Exchange: DB
Founded:
$6,631,107
4,019,141
Website: http://www.rexahn.com
Address: Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road,
Suite 455,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM REXN Common Stock Nasdaq Capital Market US USD 15. May 2005
DB R3X Common Stock Deutsche Boerse AG DE EUR 15. May 2005
Number of employees
Current staff
Staff numbers
5
Rexahn Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 21:55
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2019/03/07
Last earnings filing: 2020/02/21
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.